Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

415 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Oral azacitidine compared with standard therapy in patients with relapsed or refractory follicular helper T-cell lymphoma (ORACLE): an open-label randomised, phase 3 study.
Dupuis J, Bachy E, Morschhauser F, Cartron G, Fukuhara N, Daguindau N, Casasnovas RO, Snauwaert S, Gressin R, Fox CP, d'Amore FA, Staber PB, Tournilhac O, Bouabdallah K, Thieblemont C, André M, Rai S, Ennishi D, Gkasiamis A, Nishio M, Fornecker LM, Delfau-Larue MH, Sako N, Mule S, de Leval L, Gaulard P, Tsukasaki K, Lemonnier F. Dupuis J, et al. Among authors: fukuhara n. Lancet Haematol. 2024 Jun;11(6):e406-e414. doi: 10.1016/S2352-3026(24)00102-9. Lancet Haematol. 2024. PMID: 38796193 Clinical Trial.
Japanese phase Ib study of the oral PI3K-δ and -γ inhibitor duvelisib in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.
Makita S, Ota S, Mishima Y, Usuki K, Ennishi D, Yanada M, Fukuhara N, Yamamoto R, Takamine A, Nohara G, Izutsu K. Makita S, et al. Among authors: fukuhara n. Int J Hematol. 2024 Feb;119(2):156-163. doi: 10.1007/s12185-023-03689-6. Epub 2023 Dec 27. Int J Hematol. 2024. PMID: 38150138 Clinical Trial.
Phase 2 study of ibrutinib plus venetoclax in Japanese patients with relapsed/refractory mantle cell lymphoma.
Goto H, Ito S, Kizaki M, Yamaguchi M, Fukuhara N, Kato K, Saito T, Terui Y, Okubo S, Soshin T, Zeng J, Honda H, Badawi M, Ross JA, Izutsu K. Goto H, et al. Among authors: fukuhara n. Int J Clin Oncol. 2024 Feb;29(2):232-240. doi: 10.1007/s10147-023-02443-6. Epub 2023 Dec 29. Int J Clin Oncol. 2024. PMID: 38157190 Free PMC article. Clinical Trial.
Long-term follow-up after R-High CHOP/CHASER/LEED with Auto-PBSCT in untreated mantle cell lymphoma-Final analysis of JCOG0406.
Ogura M, Yamamoto K, Morishima Y, Wakabayashi M, Tobinai K, Ando K, Uike N, Kurosawa M, Gomyo H, Taniwaki M, Nosaka K, Tsukamoto N, Shimoyama T, Fukuhara N, Yakushijin Y, Ohnishi K, Miyazaki K, Kameoka Y, Takayama N, Hanamura I, Kobayashi H, Usuki K, Kobayashi N, Ohyashiki K, Utsumi T, Kumagai K, Maruyama D, Ohmachi K, Matsuno Y, Nakamura S, Hotta T, Tsukasaki K, Nagai H. Ogura M, et al. Among authors: fukuhara n. Cancer Sci. 2023 Aug;114(8):3461-3465. doi: 10.1111/cas.15849. Epub 2023 May 26. Cancer Sci. 2023. PMID: 37232264 Free PMC article.
Japanese subgroup analysis in the Asian phase II study of darinaparsin in patients with relapsed or refractory peripheral T-cell lymphoma.
Negoro E, Yamauchi T, Fukuhara N, Yamamoto K, Uchida T, Izutsu K, Maruyama D, Terui Y, Nakajima H, Ando K, Suehiro Y, Choi I, Kanemura N, Nakamura N, Yamamoto G, Maeda Y, Shibayama H, Nagahama F, Sonehara Y, Nagai H, Tien HF, Kwong YL, Kim WS, Tobinai K. Negoro E, et al. Among authors: fukuhara n. J Clin Exp Hematop. 2023;63(2):108-120. doi: 10.3960/jslrt.23005. J Clin Exp Hematop. 2023. PMID: 37380467 Free PMC article. Clinical Trial.
Measurable residual disease in Japanese patients with relapsed or refractory chronic lymphocytic leukemia treated with venetoclax.
Izutsu K, Yamamoto K, Kato K, Ishikawa T, Fukuhara N, Terui Y, Choi I, Okubo S, Ogawa N, Sakai M, Nishimura Y, Chyla B, Sun Y, Maruyama D. Izutsu K, et al. Among authors: fukuhara n. Int J Hematol. 2023 Oct;118(4):526-528. doi: 10.1007/s12185-023-03646-3. Epub 2023 Aug 15. Int J Hematol. 2023. PMID: 37581752 Free PMC article. No abstract available.
Five-year follow-up of a phase II study of DA-EPOCH-R with high-dose MTX in CD5-positive DLBCL.
Miyazaki K, Sakai R, Iwaki N, Yamamoto G, Murayama K, Nishikori M, Sunami K, Yoshida I, Yano H, Takahashi N, Okamoto A, Munemoto S, Sawazaki A, Suehiro Y, Fukuhara N, Wake A, Arai A, Masaki Y, Toyama K, Yokoyama A, Tsunemine H, Hasegawa Y, Matsumoto K, Yamada T, Nishimura Y, Tamaru S, Asano N, Miyawaki K, Izutsu K, Kinoshita T, Suzuki R, Ohshima K, Kato K, Katayama N, Yamaguchi M. Miyazaki K, et al. Among authors: fukuhara n. Cancer Sci. 2023 Jun;114(6):2689-2691. doi: 10.1111/cas.15784. Epub 2023 Mar 16. Cancer Sci. 2023. PMID: 36929591 Free PMC article. Clinical Trial. No abstract available.
Deciphering craniopharyngioma subtypes: Single-cell analysis of tumor microenvironment and immune networks.
Matsuda T, Kono T, Taki Y, Sakuma I, Fujimoto M, Hashimoto N, Kawakami E, Fukuhara N, Nishioka H, Inoshita N, Yamada S, Nakamura Y, Horiguchi K, Miki T, Higuchi Y, Tanaka T. Matsuda T, et al. Among authors: fukuhara n. iScience. 2024 Oct 1;27(11):111068. doi: 10.1016/j.isci.2024.111068. eCollection 2024 Nov 15. iScience. 2024. PMID: 39483146 Free PMC article.
415 results